Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded Access Study of MEK162 in NRAS-Mutant Metastatic or Unresectable Melanoma
2014-001558-40Phase 3Completed
- Sponsor
- Uzsoki Utcai Kórház
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of binimetinib in cutaneous melanoma (CM) and melanoma (MM), sponsored by Uzsoki Utcai Kórház. Started Apr 2014; status: completed.
02
Drugs
binimetinib
03
Conditions
cutaneous melanoma (CM)melanoma (MM)
Beyond the preview
Go deeper on 2014-001558-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001558-40.